Hillman Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Hillman Capital Management's BMY Position: Q2 2026 in Review
Hillman Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 15% in Q2 2026, selling an estimated $452K and leaving 45,235 shares worth $2.61M. The position accounts for 1.89% of the portfolio, ranked #22.
Hillman Capital Management first reported a position in BMY in Q4 2019 and has held it in 19 quarters since. The position peaked at $9.91M in Q1 2022. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Hillman Capital Management held 45,235 shares of Bristol-Myers Squibb worth $2.61M as of Q2 2026.
- Hillman Capital Management sold 7,867 Bristol-Myers Squibb shares in Q2 2026, an estimated $452K.
- Bristol-Myers Squibb made up 1.89% of Hillman Capital Management's portfolio in Q2 2026, its #22 holding.
- Hillman Capital Management first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 19 quarters since.
- Hillman Capital Management's Bristol-Myers Squibb position peaked at $9.91M in Q1 2022.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Hillman Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.